alexa [Role of monoclonal antibodies in the treatment of immune-mediated kidney disease: an introduction].


Journal of Nephrology & Therapeutics

Author(s): Feriozzi S

Abstract Share this page

Abstract The treatment of immune-mediated kidney disease is based on steroids and immunosuppressive drugs that interfere with the immune processes. These groups of drugs have led to significant treatment results. However, their use is not always associated with an improvement of the clinical picture and severe side effects are frequent. Recently, a new group of drugs characterized by a more restricted mechanism of action has been proposed, namely monoclonal antibodies directed against certain cellular components or molecules of inflammation. The anti-CD20 monoclonal antibody Rituximab is the most widely used in immune-mediated kidney disease, but also others, for example eculizimab (anti C5b-9), have emerged in clinical practice. The aim of this paper is to explain the rationale behind the use of these drugs starting from the pathogenetic mechanisms of immune-mediated kidney disease, to summarize their clinical use, and to raise the issue of their safety in clinical practice.
This article was published in G Ital Nefrol and referenced in Journal of Nephrology & Therapeutics

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

  • 15th International Conference on Nephrology & Therapeutics
    August 28-30, 2017 Philadelphia, USA
  • 16th European Nephrology Conference
    October 02-04, 2017 Barcelona, Spain
  • 16th European Nephrology Conference
    October 02-04, 2017 Barcelona, Spain
  • World Nephrology Congress
    Osaka, Japan Oct 09-11, 2017
  • 13th World Nephrology Conference
    October 18-19, 2017 Dubai,UAE
  • 16th International Conference on Nephrology
    NOVEMBER 02-03, 2017 Atlanta, USA

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version